Skip to main content
Premium Trial:

Request an Annual Quote

Startup Phenomics Lands an Affy Founder; Donald Schoeny Becomes President of Protedyne; and Others

NEW YORK, OCt. 30 - Beckman Coulter CEO and president John Wareham was elected to the board of the California Healthcare Institute, a major non-profit biomedical industry group.

 

Wareham has been CEO of Beckman Coulter since September 1998, and became chair in February 1999.

 

CHI advocates on behalf of state biomedical institutions and companies.

 


 

Affymetrix founder and CEO Stephen Fodor and Cambridge University geneticist John Todd both joined the scientific advisory board of Phenomix, a startup in San Diego.

 

The company was founded by the Genome Institute of the Novartis Research Foundation, the Medical Genome Centre of the Australian National University in Canberra, and Baylor College of Medicine. Its first round of financing closed last spring.

 

Phenomix's "forward genetics" approach is to develop and screen physiological models for common diseases, and then identify genes relevant to the disease.

 


 

The automation and tool company Protedyne said on Oct. 25 that it had appointed Donald Schoeny as president and CEO.

 

Schoeny was previously president of CytoLogix, which supplies instruments and reagents. He also has been vice president of commercial operations for Qiagen.

 

He replaces former president and co-founder Stan Klein, who will continue with Protedyne as vice president of business development.

 

Protedyne, which develops machines that automate genomics research, is based in Windsor, Conn.

 


 

The Duke University Institute for Genome Sciences and Policy last week said it has appointed Huntington Willard director.

 

Willard, who is currently director and president of the research institute of the University Hospitals of Cleveland, will oversee the 2-year-old center.

 

Beside focusing on the science of genomics, the Institute, which has a budget of $200 million, concentrates heavily on the ethical, legal, and policy issues of genomics, according to a Duke statement.

 

Willard, who is 49, will start in January.

 


 

Rosalie Duong will be Dharmacon's COO, the company said on Oct. 23.

 

In this newly created position, she will oversee business operations, including sales and marketing, finance, and information technology.

 

Duong was previously general manager and vice president of sales and marketing for North America for Qiagen.

 



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.